A Phase II Efficacy Trial of Pazopanib in Non-Clear Cell Metastatic Renal Cell Cancer (mRCC) PINCR
Latest Information Update: 09 Sep 2024
At a glance
- Drugs Pazopanib (Primary)
- Indications Carcinoma; Renal cell carcinoma
- Focus Therapeutic Use
- 28 Sep 2023 Planned End Date changed from 16 Nov 2023 to 16 Nov 2024.
- 27 Apr 2023 Planned End Date changed from 16 May 2023 to 16 Nov 2023.
- 16 Jun 2022 Planned End Date changed from 16 May 2022 to 16 May 2023.